This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. The FDA cleared BrainsWay D treatment of Major Depression in patients who failed to respond to one or more anti-depressants in the current episode.
Amit Etkin, MD, PhD
Amit Etkin, MD, PhD
Amit Etkin, MD, PhD is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Stanford, a member of the Stanford Neurosciences Institute, and an Investigator at the Palo Alto VA.
He has received multiple awards, most notably the NIH Director’s Pioneer Award in 2017, and is an editor at Neuropsychopharmacology.
Dr. Etkin is trained as both as a neuroscientist and psychiatrist. The overarching aim of the Etkin lab is to understand the neural basis of emotional disorders and their treatment, and to leverage this knowledge to better understand how the brain works and to develop novel treatment interventions.
In support of this goal, Dr. Etkin also collaborates with neuroscientists, engineers, psychologists, physicians and others to establish a new intellectual, scientific and clinical paradigm for understanding and manipulating human brain circuits in healthy individuals and for treating psychiatric disease.